AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05360693 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant placement with socket bone grafting
Description: After atraumatic extraction of the non-restorable tooth using periotome and luxators, osteotomy site preparation will be done and patients will receive an immediate post-extraction implant with placing bovine bone graft (Bio-oss) in the socket between the residual labial bone and implant surface. After implant insertion, the labial bone dimensions of the buccal peri-implant defect will be measured using Automated Voxel Superimposition Method of CBCT scans. All the patients in this study had two scans; primary (preoperative) scan and secondary (Postoperative) scan, with standardization of the exposure parameters. All datafrom CBCT examinations were acquired in a DICOM format which were imported to OnDemand3D ®App software (Cybermed, Seoul, Korea). In order to ensure standardization and reproducibility of the CBCT cross sectional images used in this study, superimposition of DICOM sets of each patient using Fusion module of Ondemand 3D App software was done.
Study NCT02867059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (+)-SJ000557733
Description: (+)-SJ000557733 (SJ733), in short SJ733, will be the second PfATP4 inhibitor to enter clinical development after KAE609 (Novartis) which is currently in Phase 2 stage. KAE609 (cipargamin; previously known as NITD609) is a spirotetrahydro-β-carbolines (spiroindolone). KAE609 inhibits QP15C20_SJ733_Challenge Protocol_v2.0_26July2016 Page 28 of 110 PfATP4, which results in a disruption of parasite sodium homeostasis. Compared to KAE609, SJ733 has the potential to be a very fast acting, antimalarial drug for human therapeutic application and may have a different safety profile in human participants. Finally, SJ733 blocks parasite transmission in vivo at potencies close to those where it is efficacious in blood stages, indicating its potential for transmission blockade in humans.
Study NCT05565066 — intervention group
Intervention type: DEVICE
Intervention: FNB group
Description: Fine-needle-biopsy (Echotip ProCore Needle)
Study NCT05565066 — intervention group
Intervention type: DEVICE
Intervention: FNA group
Description: Fine-needle-aspiration (Echotip Needle)
Study NCT02102685 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VAC Therapy
Description: within the first three days the VAC therapy was placed , proceeding as follows : Wound cleaning was performed with irrigating solution and replacement of the sponges every 72 hours according to evolution, photographs were taken to assess the percentage of viable tissue and granulation. A Sample to culture was taken prior to placement of VAC therapy , during the use of it and at the time of removal of the system. When the wound presents clinical signs of improvement (elimination of purulent discharge and granulation tissue ) VAC therapy was withdrawn , and follow by delayed primary closure.
Study NCT02102685 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: TRADITIONAL THERAPY
Description: after surgical drainage, a culture was taken, photographs every three days (during hospital stay ) and secretion culture; daily cleaning stipulated by the service was perform. The control of the patients were made until wound closure (presence of epithelialization tissue) .
Study NCT05464771 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery for hip and knee replacement
Description: Elective inpatient surgery for hip and knee replacement
Study NCT03067519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast track surgery
Description: early feeding and mobilization after surgery
Study NCT03766581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Oral administration
Study NCT02241538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pilates 1
Description: Combination of an educational booklet with exercises of the Pilates method. Patients will receive 6 sessions of treatment over a period of 6 weeks (1 session/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
Study NCT04144205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change of the fraction of inspired oxygen
Description: After the stabilization of cardiopulmonary bypass, in the first half of patients, fraction of inspired oxygen would be set at 0.5 and maintained for 5 minutes (T0), then it would be changed to 1.0 and maintained for 5 minutes (T1). Again, fraction of inspired oxygen would be resumed to be 0.5 and maintained for 5 minutes (T2).~In the other half of patients, the direction of change in fraction of inspired oxygen will be reversed as follows. It will be set at 1.0 and maintained for 5 minutes (T0), then changed to 0.5 and maintained for 5 minutes (T1), and finally to 1.0 and maintained for 5 minutes (T2).
Study NCT02241538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pilates 2
Description: Combination of an educational booklet with exercises of the Pilates method. Patients will receive 12 sessions of treatment over a period of 6 weeks (2 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
Study NCT02241538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pilates 3
Description: Combination of an educational booklet with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
Study NCT02241538 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients will receive an educational booklet containing information about the anatomy of the spine and pelvis and the low back pain and recommendations regarding posture and movements involved in activities of daily living. The participants in this group did not receive additional exercise.
Study NCT03244813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized activity program
Description: Targeted physical activity
Study NCT03067519 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional management
Description: Management per the primary surgeon
Study NCT01838343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Goal-directed ultrasound using a GE Vscan performed by a critical care fellow trained in ultrasonography.
Study NCT03408041 — intervention group
Intervention type: OTHER
Intervention: Medical file data extraction
Description: Medical file data extraction
Study NCT00580866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JAS Brace
Description: For approximately 6 weeks after surgery, the brace will be utilized for a period of 30 minutes, 3 times per day. Participants will also receive physical therapy 3 times per week.
Study NCT03278873 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: either AAV - CNGB3 or AAV - CNGA3
Description: Comparison of different dosages of either AAV - CNGB3 or AAV - CNGA3
Study NCT03018561 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and Cognitive testing
Description: Maximal cardiopulmonary test Rest cognitive testing
Study NCT03018561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and Cognitive testing
Description: Maximal cardiopulmonary test Rest cognitive testing
Study NCT02822924 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prostate artery embolization (PAE)
Description: Right femoral arterial puncture is performed under local anesthesia. The blood supply to the prostate is mapped by angiography of the iliac vessels and the prostate arteries. Microcatheters are used for super-selective catheterization of the right and left inferior vesicle arteries. Embolization is performed with a microcatheter to deliver microspheres of 300 micron diameter. The microsphere mixture is slowly injected under fluoroscopic guidance. The endpoint of embolization is flow stasis in the prostatic vessels with prostatic gland opacification, without reflux of the mixture to undesired arteries.
Study NCT00680966 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent Coping With Depression/Functional Family Therapy
Description: ACWD- Cognitive behavioral group therapy for depressed adolescents FFT - Family therapy to address substance use disorders in adolescents
Study NCT01076270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: Given SC
Study NCT01076270 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT01076270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Infusion of peripheral blood stem cells
Study NCT01076270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Infusion of hematopoietic stem cells
Study NCT01172054 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX128
Description: one IM injection
Study NCT01172054 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One IM injection
Study NCT05202899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: The use of sugammadex
Study NCT00751270 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdV-tk
Description: Three different dosing levels of AdV-tk (3x10e10, 1x10e11, 3X10e11) were evaluated. A single injection of AdV-tk at the assigned dose level was administered, followed by 14 days of the oral prodrug valacyclovir. Patients then received standard of care radiation therapy and chemotherapy.
Study NCT00751270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: The oral prodrug valacyclovir was given beginning 1-3 days following the AdV-tk. Valacyclovir tablets were taken three times a day for a total of 14 days.
Study NCT04745429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathing exercises, cold exposure and meditation
Description: It is a combination of exercises that include breathing exercises, cold exposure and meditation
Study NCT00812864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Pharmacokinetic of its metabolites.~Capecitabine, 1250 mg/m2 twice a day
Study NCT01487551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paquinimod
Description: Hard gelatine capsules 3.0 mg/day for 8 weeks
Study NCT01880398 — intervention group
Intervention type: OTHER
Intervention: Kshar Sutra
Description: The Kshar Sutra was a standard medicated thread smeared with Kshar of Apamarga (Achyranthus aspera), Shnuhi (Eforbia Nerrifolia) which has quality of cutting and Haridra(Curcuma Longa) which is used as a antiseptic. The ph value of the thread thus prepared was determined and its sterilization effected by ultraviolet radiation. The alkalinity of Kshar Sutra was 9.2ph.
Study NCT01325636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cell therapy
Description: Injection of specific T cell by intravenous way with a posology of 1000 to 5000 CD3 IFN γ+ / kg.~A second injection could be made at day 21
Study NCT01628484 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: prick lancet
Description: For the pricking skin preparation, sterile prick lancets for 1mm point skin testing will be used. They are used for allergy diagnostics in daily routine.
Study NCT01628484 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tape stripping
Description: For the tape stripping in the skin preparation test conventional self adhesive tape by Tesafilm® is used.
Study NCT03466697 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Glucose injection/Normal saline injection
Description: Before each PET scan, subject will be injected either glucose or normal saline.
Study NCT01705639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: All subjects receive the same dose of melatonin
Study NCT01803373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (reference)
Description: One tablet equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
Study NCT01628484 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Microneedle
Description: To induce a large number of microchannels with a maximal depth of 150µm into the cornea layer a small patch of 351 tiny needles is used, which is on the market in the US and is intended for preparing the skin for transdermal application of topical dermatology products.
Study NCT02840188 — intervention group
Intervention type: OTHER
Intervention: Radius tilt angle
Description: Fracture classification in children. Tilt angle measurement of the distal radius growth plate.
Study NCT00596674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counts
Description: 8 weeks of classes focused on health behavior change, individualized goal setting and 3 months of follow-up phone support
Study NCT00596674 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Description: 8 weeks of classes on general health information topics followed by 3 months of phone calls to solicit questions
Study NCT04497363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brainsonix Pulsar 1002
Description: Each participant will undergo 8 consecutive weekly sessions (each session is 10 minutes long) of focused ultrasound with the Brainsonix Pulsar 1002 device.
Study NCT01449396 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bed Rest
Description: Bed rest during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
Study NCT01449396 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: Sham acupuncture during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
Study NCT01449396 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
Study NCT01803373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Five 20-mg water dispersable tablets equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
Study NCT02640924 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton radiotherapy
Study NCT02640924 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Study NCT03239769 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thyroidectomy
Description: Thyroidectomies have different approaches. The aim of this study was to evaluate and compare the aesthetic effects of different access procedures in patients with differentiated thyroid carcinoma (DTC).
Study NCT03239769 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thyroidectomy
Description: Thyroidectomies have different approaches. The aim of this study was to evaluate and compare the aesthetic effects of different access procedures in patients with differentiated thyroid carcinoma (DTC).
Study NCT01803373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C
Description: 5 grams (ie,20mg/g) equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
Study NCT03186560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gekoTM
Description: The geko™ W devices are small disposable, internally powered, neuromuscular stimulators that are applied externally to the leg. The W device has a fixed 27mA current. The devices are self-adhesive and are applied to the outer/posterior aspect of the knee. This positioning enables integral electrodes to apply a stimulus to the lateral popliteal nerve (often additionally termed the common peroneal) which branches from the sciatic nerve. This nerve controls the contraction of several muscles in the lower leg.
Study NCT03890172 — intervention group
Intervention type: OTHER
Intervention: 20-100 ml venous blood will be drawn the from patient into sterilized centrifuge tube ,following centrifuge to separate PRP and at the bed side and tricked onto the ulcer twice weekly
Description: topical application of platelets rich plasma after Centrifugation at diabetic foot ulcer to study group ,history taking . Ankle brachial index (ABI) measuring and laboratory testes including hemoglobin A1c ( HgA1)c,cbc and prothrombin time( pt) and prothrombin concentration ( pc)
Study NCT03890172 — intervention group
Intervention type: OTHER
Intervention: standard treatment
Description: Subjects in the control group will receive Standard Wound Care treatment for chronic ulcers according to accepted medical practices.
Study NCT03971370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)
Description: Essen post-exposure immunization schedule at day 0,3,7,14,28.
Study NCT03971370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)
Description: Zagreb post-exposure immunization schedule at day 0,7,21.
Study NCT00497159 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo TID x 90 days
Study NCT00497159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: Dimebon 20 mg TID x 90 days
Study NCT00854568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEOP regimen
Description: cyclophosphamide 750mg/m2 IV day 1 epirubicin 70mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1\~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
Study NCT00854568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP regimen
Description: cyclophosphamide 750mg/m2 IV day 1 doxorubicin 50mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1\~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
Study NCT02954861 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00446225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg/day Patients will receive treatment until disease progression or unacceptable toxicity.~For all practical effects a treatment cycle will be defined as three weeks of continuous treatment with erlotinib
Study NCT00446225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Gemcitabine 1000 mg/m2 days 1 and 8 and Carboplatin AUC = 5 day 1, every 21 days.~Docetaxel (75 mg/m2) /carboplatin (AUC=6); Gemcitabine (1000 mg/m2; day 1 and 8) / Carboplatin (AUC=5)~Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
Study NCT00446225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabin
Description: Cisplatin (75 mg/m2) / Gemcitabine (1250 mg/m2; day 1 and 8) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
Study NCT00446225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
Study NCT00446225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2) Patients in the chemotherapy arm will receive the treatment until disease progression or unacceptable toxicity occurs, or until a maximum of 4 treatment cycles are given.
Study NCT00518336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling at Visit 3, 5 and 7.
Study NCT00518336 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood sampling
Description: Blood sampling at Visit 3, 5 and 7.
Study NCT00518336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of cervical specimen
Description: Collection of cervical specimen at Visit2, 3, 4, 5, 6 and 7.
Study NCT00518336 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Collection of cervical specimen
Description: Collection of cervical specimen at Visit2, 3, 4, 5, 6 and 7.
Study NCT03971370 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human diploid cell rabies vaccine (Chengdu Kanghua Biological Products Co., Ltd.)
Description: Essen post-exposure immunization schedule at day 0,3,7,14,28.
Study NCT03508921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Periprocedural Antibiotics
Description: One the day of injection, after eligibility is determined and consent obtained, research staff will refer to the randomization list to determine to which arm the patient is randomized. Patients randomized to the Procedural Antibiotics Only arm will receive a single dose of trimethoprim/sulfamethoxazole (800/160mg) peri-procedurally at the time of the first injection.
Study NCT01422785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clindamycin phosphate 1.2%/tretinoin 0.025% gel alone
Description: Once daily application of the clindamycin phosphate 1.2%/tretinoin 0.025% gel in the evening
Study NCT01422785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
Description: wash face with the benzoyl peroxide foaming cloth then rinse. then apply clindamycin phosphate 1.2%/tretinoin 0.025% gel. both done in the evening.
Study NCT00518336 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix
Description: Three doses administered intramuscularly at 0, 1 and 6 months.